Featured Firms
Presented by BigVoodoo
A Philadelphia judge has announced the certification of a class of asymptomatic users of the cholesterol-reducer Baycol who seek medical monitoring benefits from pharmaceutical giants Bayer and GlaxoSmithKline. Bayer removed Baycol from the market in 2001, following reports that the drug was linked to a potentially fatal disease marked by destruction of the muscles. Plaintiffs also allege that Baycol lessens the production of a coenzyme, the depletion of which is tied to congestive heart failure.
December 13, 2004 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS